Biotech | November 30, 2021
Thermo Fisher Scientific’s new CRISPR Genome editing protein
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
_256_384.jpg)
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
The aim is to create an awareness programme that will drive diabetic patients to get their eyes tested regularly
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
This agreement marks a milestone for Baidu to use its strengths in computational biology to optimize mRNA vaccine and therapy designs
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Owkin builds best-in-class predictive biomedical AI models and robust data sets
The loan will fund at least 667 million Covid-19 vaccine doses for an estimated 317 million people
Officials from ACG signed the MoU with the Maharashtra government for the Rs 600 crore investment in the backward region of Marathwada
Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales
Subscribe To Our Newsletter & Stay Updated
